Abstract
Background: Activation of sodium hydrogen exchanger (NHE) contributes to cardiac ischemia reperfusion (I/R) injury. We recently reported NHE inhibition properties of the diabetic drug SGLT2 inhibitor empagliflozin (EMPA). Classic NHE inhibitors delay ischemic contracture and reduce I/R injury in the heart, dependent on the degree of ischemic glycogen depletion. We examined in normal-/low-glycogen hearts whether EMPA delays ischemic contracture and reduces I/R injury.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
